Home・Elenco Azioni・Genmab A-S

Genmab A-S

Chiusa

2,235 -1.76

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2264

Massimo

2286

Metriche Chiave
By Trading Economics
Entrata	243M 295M
Vendite	259M 1.2B
P/E Media del settore	26.002 56.432
EPS	34.85
Margine di Profitto	25.541
Dipendenti	3,119
EBITDA	216M 431M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-1.49% downside

Dividendi
By Acuity
Utili prossimi	5 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	17B 130B
Apertura precedente	2236.76
Chiusura precedente	2235

Genmab A-S Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 set 2026, 23:31 UTC

China's Loan Prime Rate announcement on September 21, 2026, is anticipated at 0.03%, amid global tightening trends influenced by rising inflation and Japan's recent rate hike to 1.25%.

19 set 2026, 23:31 UTC

China's Loan Prime Rate expected to hold at 3.50% on September 21, amid stable market sentiment and focus on international cooperation.

19 set 2026, 23:11 UTC

U.S. Mortgage Rates Hit 6.97% Amid Fed Rate Hike and Inflation Concerns, Signaling Potential Further Increases Ahead

19 set 2026, 23:11 UTC

Cautious Market Sentiment Ahead of Chicago Fed National Activity Index Release Amid Disappointing Economic Indicators

19 set 2026, 23:01 UTC

Avalanche is advancing sharply, continuing its strong upward trend, despite earlier pulling back from a session high, and trading well above its 20-day moving average.

19 set 2026, 23:01 UTC

Correlated Moves

XRP is advancing, continuing its upward trend since Friday's close, influenced by ongoing geopolitical tensions and recent interest rate hikes by major central banks.

19 set 2026, 22:51 UTC

Correlated Moves

The Russell 2000 Index is little changed in after-market hours, remaining near the lower end of its one-month range amid ongoing geopolitical tensions.

19 set 2026, 22:51 UTC

Correlated Moves

Macro News

The Dow Jones Index (US) is trading lower in after-market hours, reflecting minimal movement since Friday's close amid ongoing geopolitical tensions and a new Lockheed Martin contract.

19 set 2026, 22:51 UTC

The FTSE 100 Index is trading lower in after-market hours, positioned below its 20-day moving average amid ongoing geopolitical tensions affecting energy prices.

19 set 2026, 22:31 UTC

UK Consumer Confidence Index Forecasted at -16.0 Amid Cautious Market Sentiment and Rising Cost-of-Living Concerns

19 set 2026, 21:41 UTC

Australia's S&P Global Manufacturing PMI Flash set for September 22, with market expectations at neutral 50 amid cautious optimism and inflation concerns.

19 set 2026, 21:41 UTC

Australia's S&P Global Services PMI Flash release on September 22 faces cautious optimism amid mixed economic signals and global inflation concerns.

19 set 2026, 21:21 UTC

Brazil's Central Bank to Release COPOM Meeting Minutes Amid Global Interest Rate Shifts, Influencing Market Sentiment on SELIC Decisions

19 set 2026, 21:11 UTC

UK CBI Distributive Trades Forecasts -50.0 Amidst Recent Retail Sales Rebound, Indicating Mixed Consumer Sentiment Ahead of Q4

19 set 2026, 20:41 UTC

UK Manufacturing Sector Faces Caution Ahead of September 2026 CBI Industrial Trends Orders Forecasted at -35.0 Amid Mixed Economic Signals and Rising Cost Pressures.

19 set 2026, 20:41 UTC

API Crude Oil Stock Change Data Release on September 22, 2026, Amidst Volatile Market Influenced by Geopolitical Tensions and Mixed Investor Sentiment.

19 set 2026, 19:41 UTC

South Korea's Consumer Confidence Index set for release amid bearish market sentiment and rising interest rates, signaling potential consumer caution.

19 set 2026, 19:41 UTC

Correlated Moves

EUR/NZD is roughly flat since Friday's close, maintaining stability while the market is closed for the weekend and reflecting its position near the upper end of its one-month range.

19 set 2026, 19:41 UTC

Macro News

Volkswagen's fiscal outlook revision due to Porsche AG goodwill impairment is contributing to a decline in the IBEX 35 Index amid rising geopolitical tensions.

19 set 2026, 19:41 UTC

Macro News

The A50 Index (China) is modestly higher in after-market trading, amid rising geopolitical tensions and central bank interest rate hikes affecting risk assets.

19 set 2026, 19:11 UTC

Germany's Ifo Business Climate Index set for September 24 release amid cautious market sentiment and rising inflation expectations.

19 set 2026, 18:51 UTC

Investors Brace for Cautious S&P Global Composite PMI Flash Release Amid Rising Inflation Concerns in Euro Area

19 set 2026, 18:51 UTC

South Africa's Inflation Rate Set for Release Amid Cautious Market Sentiment Following July Decline to 4.3%.

19 set 2026, 18:51 UTC

Investors Brace for S&P Global Services PMI Flash Release Amid Rising Inflation Concerns and Mixed Economic Signals in Euro Area

19 set 2026, 18:51 UTC

Euro Area's S&P Global Manufacturing PMI Flash set for September 23, with forecasted growth amid rising inflation concerns and cautious investor sentiment.

19 set 2026, 18:51 UTC

South Africa's Inflation Rate Release on September 23, 2026 Sparks Caution Among Investors Amid Global Economic Pressures.

19 set 2026, 18:41 UTC

SNB Expected to Maintain 0% Interest Rate Amid Low Inflation and Strong Franc Ahead of September Decision

19 set 2026, 18:31 UTC

Spain's Balance of Trade report on September 22, 2026, raises concerns over systemic trade deficits amid rising inflation and cautious market sentiment.

19 set 2026, 18:21 UTC

Germany's S&P Global Services PMI Flash set for September 23, with cautious market sentiment amid rising inflation expectations and mixed economic indicators.

19 set 2026, 18:21 UTC

Germany's S&P Global Composite PMI Flash Release on September 23 Expected to Reflect Economic Challenges Amid Inflation and Geopolitical Uncertainty.

Confronto tra pari

Modifica del prezzo

Genmab A-S Previsione

Obiettivo di Prezzo

By TipRanks

-1.49% in calo

Previsioni per 12 mesi

Media 2,493.35 DKK -1.49%

Alto 3,320 DKK

Basso 308.417 DKK

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Genmab A-S - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Genmab A-S - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.